Pulmatrix Inc., a biopharmaceutical company focused on the development of novel inhaled therapeutic products, has announced the termination of its Merger Agreement with Cullgen Inc., which was announced in November 2024. This termination follows the announcement that Pulmatrix and Cullgen had mutually agreed to waive the “No Solicitation” clause in the Merger Agreement in order to permit each party to explore alternate transactions in the period until closing. At this time, Pulmat...